MAZE
NASDAQ · Pharmaceuticals
Maze Therapeutics Inc
$34.45
+1.92 (+5.90%)
Financial Highlights (FY 2026)
Revenue
190.13M
Net Income
20.86M
Gross Margin
—
Profit Margin
11.0%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 45.9% | 45.9% | 45.9% |
| Operating Margin | 34.4% | 19.7% | 21.1% | 21.4% |
| Profit Margin | 11.0% | 20.1% | 16.9% | 17.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 190.13M | 546.10M | 525.77M | 523.61M |
| Gross Profit | — | 250.88M | 241.55M | 240.55M |
| Operating Income | 65.37M | 107.81M | 110.83M | 112.09M |
| Net Income | 20.86M | 109.70M | 88.79M | 91.93M |
| Gross Margin | — | 45.9% | 45.9% | 45.9% |
| Operating Margin | 34.4% | 19.7% | 21.1% | 21.4% |
| Profit Margin | 11.0% | 20.1% | 16.9% | 17.6% |
| Rev Growth | — | +21.9% | +7.3% | -7.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 615.27M | 505.54M | 518.26M |
| Total Equity | — | 833.25M | 765.68M | 754.51M |
| D/E Ratio | — | 0.74 | 0.66 | 0.69 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 69.11M | 173.82M | 160.69M | 151.47M |
| Free Cash Flow | — | 65.89M | 67.30M | 41.13M |